Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A.

about

In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients.Lonoctocog Alfa: A Review in Haemophilia A.Lonoctocog alfa (rVIII-SingleChain) for the treatment of haemophilia A.

P2860

Q45869569-47E7895C-F43A-48A9-96E9-140DDE79E291 Q45871869-84D9BEC2-DA04-42ED-81F5-BAFA59329B89 Q50139622-784565AC-1A67-4627-B174-FE87B3F92DF7

P2860

Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A.

Item

http://www.wikidata.org/entity/Q45865167

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Population pharmacokinetics of ...... ents with severe hemophilia A.

@en

Population pharmacokinetics of ...... ents with severe hemophilia A.

@nl

type

Item

label

Population pharmacokinetics of ...... ents with severe hemophilia A.

@en

Population pharmacokinetics of ...... ents with severe hemophilia A.

@nl

prefLabel

Population pharmacokinetics of ...... ents with severe hemophilia A.

@en

Population pharmacokinetics of ...... ents with severe hemophilia A.

@nl

P1476

Population pharmacokinetics of ...... ents with severe hemophilia A.

@en

P2093

A Feussner

http://www.w3.org/2001/XMLSchema#string

A Veldman

http://www.w3.org/2001/XMLSchema#string

J Roberts

http://www.w3.org/2001/XMLSchema#string

J Sidhu

http://www.w3.org/2001/XMLSchema#string

K St Ledger

http://www.w3.org/2001/XMLSchema#string

M Tortorici

http://www.w3.org/2001/XMLSchema#string

Y Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses.

Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS.

Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.

Haemophilias A and B.

The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods.

Diagnosing model diagnostics.

Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A.

Mechanistic basis of using body size and maturation to predict clearance in humans.

Man versus beast: pharmacokinetic scaling in mammals.

Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII.

P304

1106-1114

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JTH.13662

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28244200

http://www.w3.org/2001/XMLSchema#string

P921

hemophilia

hemophilia A

Coagulation factor VIII

Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A.

about

P2860

P2860

Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921